In Q1 FY2026 (ended March 31, 2026), Ovid Therapeutics reported zero revenue, a net loss of $16.99 million, and an operating loss of $17.85 million. The company held $94.06 million in cash and $198.27 million in equity, with no long-term debt. Compared to the prior year, revenue declined 100%, while net loss and operating loss increased by 66% and 42%, respectively.
•Revenue was $0, down 100% year-over-year.
•Net loss of $16.99 million, 66% worse than Q1 FY2025.
•Operating loss of $17.85 million, 42% higher year-over-year.
•Cash and cash equivalents stood at $94.06 million as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Ovid Therapeutics Inc., a biopharmaceutical company develops small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies
OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton Marinus Pharmaceuticals, Inc. Incorporated in 2014, the company is headquartered in New York, New York.
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, specifically epilepsies and seizure-related neurological conditions. The company's pipeline includes OV329, a GABA-AT inhibitor currently in Phase 1 clinical trials for drug-resistant epilepsies in adults and infants, and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator in Phase 1 trials for psychosis associated with Parkinson's disease, Lewy body dementia, and acute schizophrenia. Ovid also has license and collaboration agreements with partners such as AstraZeneca AB, H. Lundbeck A/S, Northwestern University, Graviton, and Marinus Pharmaceuticals, Inc.
Where is Ovid Therapeutics listed and what currency does it trade in?
Ovid Therapeutics Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol OVID. The company trades in US Dollars (USD), which is the standard currency for stocks listed on US exchanges. As a NasdaqCM-listed company, Ovid is subject to the reporting and governance requirements of the US Securities and Exchange Commission, providing transparency for investors.
What sector and industry does Ovid Therapeutics belong to?
Ovid Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies like Ovid use biological processes and molecular biology to develop drugs and therapies. In Ovid's case, the focus is on small molecule medicines for neurological disorders, which distinguishes it from biotech firms working on biologics or gene therapies. The company's work in epilepsy and seizure-related conditions places it at the intersection of neurology and pharmacology.
Where is Ovid Therapeutics headquartered and what markets does it serve?
Ovid Therapeutics Inc. is headquartered in New York, New York, United States. The company primarily serves the US market, as indicated by its country and region classification. Its clinical trials for OV329 and OV4071 are conducted in the United States, and its collaborations with US-based institutions like Northwestern University further emphasize its domestic focus. While the company may eventually expand globally, its current operations and regulatory filings are centered on the US healthcare system.
What is Ovid Therapeutics' business model and how does it generate revenue?
Ovid Therapeutics operates as a biopharmaceutical company that generates revenue primarily through licensing agreements and collaborations. The company has entered into license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, Graviton, and Marinus Pharmaceuticals, Inc. These partnerships likely involve upfront payments, milestone payments, and royalties on future product sales. As a development-stage company, Ovid does not yet have approved products on the market; its pipeline candidates OV329 and OV4071 are in Phase 1 clinical trials, meaning the company is still in the early stages of drug development and has not generated revenue from product sales.